VEGFA and renal cell carcinoma: Although the VEGF pathway plays a role in sustaining immunosuppression within the TME, its activity is less prominent in CRC than in renal cell carcinoma [31], where ICIs plus anti-VEGF TKI therapy has become the standard treatment approach.